Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [1] Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
    Baez-Gutierrez, Nerea
    Rodriguez-Ramallo, Hector
    Antonia-Perez Moreno, Maria
    Arboli, Eduardo-Rodriguez
    Abdel-Kader Martin, Laila
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [2] Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy
    Kristensen, Daniel Tuyet
    Brondum, Rasmus Froberg
    orskov, Andreas Due
    Marcher, Claus Werenberg
    Schollkopf, Claudia
    Sorensen, Anne Louise Tolboll
    Severinsen, Marianne Tang
    Bogsted, Martin
    Roug, Anne Stidsholt
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 573 - 582
  • [3] Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
    Rahme, Ramy
    Braun, Thorsten
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [4] Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia
    Yu, Guopan
    Yin, Zhao
    Jin, Hua
    Yu, Sijian
    Li, Yuhua
    Nie, Danian
    Guo, Ziwen
    Sun, Zhiqiang
    Meng, Qingxiang
    Zhao, Weihua
    Lin, Dongjun
    Xu, Na
    Zhang, Yu
    BLOOD, 2022, 140 : 11796 - 11796
  • [5] Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent
    On, Sandy
    Rath, Carolyn G.
    Lan, Michelle
    Wu, Bobby
    Lau, Kimberly M.
    Cheung, Edna
    Alegria, William
    Young, Rebecca
    Tan, Marisela
    Kim, Carrie
    Phun, Jennifer
    Patel, Nimish
    Mannis, Gabriel
    Logan, Aaron C.
    Kennedy, Vanessa
    Goodman, Aaron
    Taplitz, Randy A.
    Young, Patricia A.
    Wen, Raymond
    Saunders, Ila M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (01) : 63 - 70
  • [6] Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    He, Aili
    Wang, Fangxia
    HEMATOLOGY, 2023, 28 (01)
  • [7] Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia
    Karol, Seth E.
    Khaw, Seong L.
    Zwaan, C. Michel
    Baruchel, Andre
    Bittencourt, Henrique
    Cooper, Todd M.
    Flotho, Christian
    Fraser, Christopher
    Forlenza, Christopher J.
    Goldsmith, Kelly C.
    Macy, Margaret E.
    Morgenstern, Daniel A.
    O'Brien, Maureen M.
    Petit, Arnaud
    Ziegler, David S.
    Reinhardt, Dirk
    Opferman, Joseph T.
    Rubnitz, Jeffrey E.
    Onishi, Maika
    Dunshee, Diana R.
    Dunbar, Fengjiao
    Vishwamitra, Deeksha
    Ross, Jeremy A.
    Chen, Xin
    Unnebrink, Kristina
    Kammerlander, Maja
    Salem, Ahmed Hamed
    Palenski, Tammy L.
    Sunkersett, Gauri
    Place, Andrew E.
    PEDIATRIC BLOOD & CANCER, 2025,
  • [8] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
    Graveno, Molly E.
    Carulli, Alison
    Freyer, Craig W.
    Mangan, Brendan L.
    Nietupski, Robert
    Loren, Alison W.
    Frey, Noelle, V
    Porter, David L.
    Gill, Saar, I
    Hexner, Elizabeth O.
    Luger, Selina M.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Perl, Alexander E.
    Babushok, Daria, V
    Pratz, Keith W.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
  • [9] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Luo, Tingyue
    Yu, Sijian
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Shao, Ruoyang
    Du, Xin
    Jin, Hua
    Liu, Qifa
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339
  • [10] Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients
    LeBlanc, Francis R.
    Breese, Erin H.
    Burns, Karen C.
    Chang, Ellen K.
    Jones, LaQuita M.
    Lee, Lynn
    Mizukawa, Benjamin
    Norris, Robin E.
    O'Brien, Maureen M.
    Phillips, Christine L.
    Perentesis, John P.
    Rubinstein, Jeremy
    Pommert, Lauren
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 1055 - 1066
12345